Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability